
Table of Contents

Section I: General Information

Chapter 1	EMA and Other EU Regulatory Bodies	1
	<i>By Naheed Sayeed-Desta and Ajay Pazhayattil, MPharm</i>	
Chapter 2	History of EU Regulation	13
	<i>By Sabina Hoekstra-van den Bosch, MSc, PharmD, FRAPS</i>	
Chapter 3	Overview of Drug and Biologic Regulatory Pathways.....	29
	<i>By Gowri Sukumar, MS, RAC</i>	
Chapter 4	Preparing for EMA and Other Agency Meetings	49
	<i>By Anne Marie Woodland, MS, RAC</i>	
Chapter 5	EU Pricing and Reimbursement.....	57
	<i>Updated by Carole Jones, MBA</i>	
Chapter 6	Health Technology Assessment.....	75
	<i>Updated by Carole Jones, MBA</i>	
Chapter 7	The Paediatric Regulation.....	87
	<i>By Karl-Heinz Huemer, PhD, MD</i>	
Chapter 8	Advertising and Promotion	97
	<i>Updated by Salma Michor, PhD, RAC</i>	
Chapter 9	Enforcement and National Authorities.....	107
	<i>Updated by Sabina Hoekstra-van den Bosch, MSc, PharmD, FRAPS</i>	
Chapter 10	European Union Falsified Medicines Directive: Requirements and Implications for Multi-Stakeholder Healthcare Delivery.....	113
	<i>Updated by Bernard Naughton, MPharm, MRPharmS, DipCllinPhar, PhD Candidate and David A. Brindley, DPhil, MEng</i>	
Chapter 11	Regulatory Strategy	125
	<i>By Rajaram Balasubramanian, RAC and Sharad Mi. Shukla, RAC (US, EU)</i>	

Section II: Medical Devices

Chapter 12	The New Medical Device Regulation and In Vitro Diagnostic Device Regulation	129
	<i>By Gert Bos, PhD, FRAPS and Erik Vollebregt, LLM</i>	
Chapter 13	The European Medical Devices Legal System	137
	<i>By Gert Bos, PhD, FRAPS and Erik Vollebregt, LLM</i>	
Chapter 14	Medical Devices: Legislation and Classification.....	165
	<i>Updated by Nicole Béard, MSc, PhD</i>	
Chapter 15	In Vitro Diagnostic Medical Devices.....	177
	<i>Updated by Erik Vollebregt, LLM</i>	

Chapter 16	General Safety and Performance Requirements and Technical Documentation (<i>MRD</i> and <i>IVDR</i>) 187 <i>By Wan-Li Liao, MD, PhD</i>	187
Chapter 17	Medical Device Preclinical Testing..... 193 <i>By Sharad Mi. Shukla, RAC (US, EU) and Rajaram Balasubramanian, RAC</i>	193
Chapter 18	Clinical Evaluation and Clinical Evaluations 201 <i>By Loes Pelgrim, MSc and Gert Bos, PhD, FRAPS</i>	201
Chapter 19	Medical Device Conformity Assessment Procedure 207 <i>Updated by Gert Bos, PhD, FRAPS</i>	207
Chapter 20	Medical Device Compliance: Postmarket Requirements 221 <i>Updated by Peter Osterhoff, PhD and Gert Bos, PhD, FRAPS</i>	221
Chapter 21	Medical Device National Particularities..... 233 <i>Updated by Elizabeth Goldstein, RAC</i>	233
Section III: Medicinal Products		
Chapter 22	Overview of Authorisation Procedures for Medicinal Products 239 <i>Updated by Elisabet Faulkner, IQS, MSc, RAC</i>	239
Chapter 23	Adaptive and Alternative Pathways..... 257 <i>By Kathrin Schalper, PhD, RAC</i>	257
Chapter 24	Preclinical Testing and Good Laboratory Practices..... 261 <i>Updated by Jocelyn Jennings, MS, RAC</i>	261
Chapter 25	Medicinal Product Clinical Trials 269 <i>By Isabelle B. Lefebvre, MScRA, RAC (US, EU)</i>	269
Chapter 26	Registration Procedures for Medicinal Products 297 <i>By Gowri Sukumar, MS, RAC</i>	297
Chapter 27	Quality Systems and Inspectorate Process—Pharmaceuticals..... 319 <i>By Ajay Babu Pazhayattil, MPharm, CPGP, CKM and Naheed Sayeed-Desta</i>	319
Chapter 28	Generic Medicinal Products 329 <i>By Michael Craig</i>	329
Chapter 29	Nonprescription Medicinal Products..... 347 <i>Updated by Salma Michor, PhD, RAC</i>	347
Chapter 30	Marketing Authorisations for Products Derived From Biotechnology..... 357 <i>By Nicole Béard, MSc, PhD</i>	357
Chapter 31	Pharmaceutical Postauthorisation Requirements and Compliance With the Marketing Authorisations 365 <i>Updated by Irena Medarevic-Milobratovic</i>	365
Chapter 32	Pharmacovigilance..... 379 <i>By Jocelyn Jennings, MS, RAC</i>	379
Chapter 33	Regenerative Medicine Regulation: Cell Therapy, Gene Therapy and Tissue Engineering..... 393 <i>By James A. Smith, RAC, Joseph H. Senesac, MBA, RAC (US, EU) and Sarah A. Robinson, MBioChem, RAC (EU)</i>	393
Chapter 34	Human Tissue Regulation 415 <i>Updated by Lisa Graney, RAC and Brittany Beasley, RAC</i>	415
Chapter 35	Vaccines 431 <i>Updated by Frédéric Béard</i>	431

Section IV: Foods

Chapter 36	Food Supplements, Health Claims and Botanicals.....	443
	<i>By Patrick Coppens and Manfred Ruthsatz, PhD, RAC, FRAPS</i>	
Chapter 37	Food for Special Medical Purposes	451
	<i>By Cathy Bushell and Manfred Ruthsatz, PhD, RAC, FRAPS</i>	

Section V: Other Product Classifications

Chapter 38	Products Manufactured From Human Blood or Plasma	459
	<i>Updated by Sarah A. Robinson, MBioChem, RAC (EU) and R. Helen Belfield, PhD</i>	
Chapter 39	Orphan Medicinal Products	467
	<i>Updated by Nicole Béard, MSc, PhD</i>	
Chapter 40	Combination Products	479
	<i>Updated by Richard Vincins, CQP, MCQI, CBA, CQA, RAC (US, EU)</i>	
Chapter 41	Cosmetics Regulation in the EU	489
	<i>Updated by Frédéric Béard</i>	
Chapter 42	Veterinary Medicinal Products	497
	<i>Updated by Nicole Béard, MSc, PhD</i>	

Section VI: Resources

Chapter 43	Regulatory Information Resources	519
	<i>By Pallavi Trivedi, MPharm, RAC</i>	

Appendices

Comparative Matrix of EU Legislation Across Product Lines	543
Glossary	585
Index	605

Figures

Figure 1-1.	EEA Healthcare Product Regulatory Framework.....	3
Figure 1-2.	EMA Mission.....	3
Figure 1-3.	EMA Organisational Structure.....	8
Figure 1-4.	ITF Objectives	10
Figure 3-1.	Timeline of Scientific Advice Procedures	31
Figure 3-2.	Regulatory Pathway for an Orphan Product.....	34
Figure 3-3.	Assessment of Eligibility: 40-Day Procedure.....	37
Figure 3-4.	CTD Hierarchical Structure.....	38
Figure 3-5.	Name Review Group Procedure	42
Figure 3-6.	Inspection Timelines	43
Figure 5-1.	Factors influencing Medicinal Product Pricing	59
Figure 5-2.	Overview of ERP Across Europe	60
Figure 5-3.	Summary of Economic Evaluation Methods	63
Figure 5-4.	Types of Cost Containment Policies Adopted by Member States.....	65
Figure 5-5.	German Pricing for Medicinal Products Under AMNOG	67
Figure 6-1.	Process Map for France	81
Figure 6-2.	Process Map for Germany	82
Figure 6-3.	Mean Length of Time from EMA Authorisation to HTA Decision for Oncology Products	84
Figure 7-1.	PIP Procedure	91
Figure 10-1.	Comparison of EU FMD and Other Countries' Falsified Medicines' Legislation.....	115
Figure 10-2.	Figure 10-2 Routes In the Medicinal Product Supply Chain by Which Falsified Active Substances May Reach Patients.....	116
Figure 10-3.	An Example of the Common Logo Online Retailers of Medicines Must Display.....	119
Figure 10-4.	Flowchart Representing Product and Information Flow With Unique Product Identifiers and Accompanying Verification and Repository Systems.....	120
Figure 10-5.	Examples of Stratified Medicines and Companion Diagnostics	122
Figure 12-1.	Supply Chain Controls.....	131
Figure 12-2.	Proposed <i>EU IVDR</i> Classification Rules.....	132
Figure 12-3.	Governance Structure for the <i>EU MDR</i> and <i>EU IVDR</i>	134
Figure 13-1.	Simplified EU Legislative Process	139
Figure 13-2.	Flow Chart for the Conformity Assessment Procedures Provided for In Directive 93/42/EEC on Medical Devices..	141

Figure 13-3.	Flow Chart for the Conformity Assessment Procedures Provided for In Directive 90/385/EEC on Active Implantable Medical Devices.....	142
Figure 13-4.	Flow Chart for the Conformity Assessment Procedures Provided for In Directive 98/79/EEC on In Vitro Diagnostic Medical Devices.....	143
Figure 14-1.	Classification Guidance Chart—Noninvasive Devices per <i>MDD</i>	170
Figure 14-2.	Classification Guidance Chart—Rule 5 per <i>MDD</i>	171
Figure 14-3.	Classification Guidance Chart—Rule 5 per <i>MDD</i>	171
Figure 14-4.	Classification Guidance Chart—Rule 7 per <i>MDD</i>	172
Figure 14-5.	Classification Guidance Chart—Rule 8 per <i>MDD</i>	173
Figure 14-6.	Classification Guidance Chart—Active Devices per <i>MDD</i>	174
Figure 14-7.	Classification Guidance Chart—Special Rules per <i>MDD</i>	174
Figure 14-8.	IVD Classification Chart per <i>MDD</i>	175
Figure 19-1.	Class III Device Conformity Assessment Procedure Options.....	212
Figure 19-2.	Class IIb Conformity Assessment Procedures.....	213
Figure 19-3.	Class IIa Conformity Assessment Procedure.....	213
Figure 19-4.	Class I Device, Self-Declaration or Self-Certification.....	214
Figure 19-5.	AIMDD Conformity Assessment Procedure.....	214
Figure 19-6.	IVD Conformity Assessment Procedure.....	215
Figure 19-7.	Self-Testing IVD Conformity Assessment Procedure.....	215
Figure 19-8.	IVDD Annex II List B Conformity Assessment Procedures.....	216
Figure 19-9.	High-Risk IVD Conformity Assessment Procedure.....	217
Figure 25-1.	Clinical Trial Legislative Improvements.....	271
Figure 25-2.	Regulation (EU) 536/2014.....	272
Figure 25-3.	Clinical Trial Authorisation Procedure.....	284
Figure 25-4.	Clinical Trial Application Scientific Assessment.....	285
Figure 25-5.	Clinical Trial Application Ethics Committee Assessment.....	286
Figure 26-1.	Initial Marketing Authorisation Application Through the Centralised Procedure.....	312
Figure 26-2.	Initial Marketing Authorisation Application Through the Decentralised Procedure.....	313
Figure 26-3.	Initial Marketing Authorisation Application Through National Procedure and Mutual Recognition Procedure.....	314
Figure 32-1.	Pharmacovigilance System Master File.....	381
Figure 32-2.	ICSR Expedited Submissions Requirements.....	386
Figure 32-3.	Signal Management Lifecycle.....	388
Figure 33-1.	Key EU ATMP Regulations, Directives and Decisions.....	395
Figure 33-2.	Decision Tree for Classification of TEPs and CTMPs.....	398
Figure 33-3.	Decision Tree for GTMP Classification.....	402
Figure 35-1.	General Principles of VAMF Certification.....	433
Figure 35-2.	Procedure for Seasonal Influenza Vaccines in the European Union (EMA/56792/2013).....	435
Figure 39-1.	Simplified View of the Designation Criteria.....	479
Figure 43-1.	Committees and Working Groups.....	524

Tables

Table 4-1.	Scientific Advice Timetable.....	52
Table 5-1.	Overview of Reference Pricing and Country Baskets in Europe.....	61
Table 6-1.	HTA and Associated Organisations in Key European States.....	77
Table 6-2.	Link Between HTA and Pricing & Reimbursement Processes in the EU5 Countries.....	78
Table 6-3.	Comparison of HTA models in the EU5 countries (Germany, France, UK, Italy and Spain).....	79
Table 6-4.	A Lack of Consistency in Approach Among HTA agencies.....	83
Table 10-1.	Definitions of Key Terms in This Chapter.....	116
Table 10-2.	Worldwide Examples of SFFC Medicines From 2008 to Present.....	117
Table 10-3.	Different Medicinal Product Supply Chain Stakeholder Requirements Under the <i>FMD</i>	118
Table 10-4.	<i>FMD</i> Definitions of Active Substances and Excipients.....	119
Table 10-5.	EU Initiatives Relevant to the <i>FMD</i>	120
Table 10-6.	List and Status of Third Countries Requested to be Listed.....	121
Table 13-1.	New Approach Areas.....	140
Table 13-2.	EU Member States and Affiliated Countries Competent Authorities.....	145
Table 13-3.	European Commission Working Groups and Their Activities.....	150
Table 13-4.	European Industrial Trade Associations.....	152
Table 13-5.	MEDDEV Guidance Documents.....	157
Table 13-6.	European Commission Consensus Statements.....	158
Table 13-7.	Informative Documents Issued by the European Commission.....	159
Table 13-8.	NBOG Documents (NBOG Best Practice Guides).....	160
Table 15-1.	Examples of General Laboratory Use Products and IVD Medical Devices.....	179
Table 16-1.	Example of a Partial GSPR Checklist.....	188

Table 19-1.	Conformity Assessment Procedures	209
Table 19-2.	AIMDD Conformity Assessment Documentation	210
Table 19-3.	MDD Conformity Assessment Documentation	211
Table 19-4.	IVDD Conformity Assessment Documentation	212
Table 19-5.	Internal Production Control	216
Table 19-6.	EC Type-Examination	216
Table 19-7.	Production Quality Assurance	216
Table 19-8.	Product Quality Assurance	217
Table 19-9.	Product Verification	217
Table 19-10.	Full Quality Assurance System	218
Table 19-11.	Authorised Representatives	218
Table 20-1.	Provisions for Providing Feedback about Medical Devices	222
Table 20-2.	Eudamed Data Repository	225
Table 20-3.	Comparison of Safeguard Clause and Health Monitoring Measures	230
Table 21-1.	EU Outermost Regions	234
Table 21-2.	Current Directives and New Regulations for Medical Devices, AIMDs and IVDs.....	234
Table 21-3.	Translation Requirements for Medical Devices, AIMDs and IVDs.....	235
Table 21-4.	National Languages of the EU, Iceland, Liechtenstein and Norway.....	236
Table 22-1.	Standard Timetable for Evaluation of a Centralised Application`	246
Table 22-2.	Mutual Recognition Procedure Flowchart	249
Table 22-3.	Decentralised Procedure Flowchart	251
Table 25-1.	Summary of Selected Significant Changes Under Regulation (EU) No 536/2014 ECTR.....	273
Table 25-2.	Definitions of Selected <i>Clinical Trials Directive</i> and <i>ECTR</i> Terms	294
Table 25-3.	General Contents of Applications to Ethics Committees and National Competent Authorities	279
Table 25-4.	Contents of Clinical Trial Application Dossier per the <i>ECTR</i>	287
Table 25-5.	Contents of DSUR	291
Table 26-1.	EU Module 1 Contents.....	307
Table 26-2.	EU eCTD Envelope Information.....	308
Table 27-1.	MRA Status	325
Table 28-1.	Legal Basis of EU Applications	334
Table 29-1.	Some Common Health Conditions Treated Using Nonprescription Medication	349
Table 29-2.	Comparison of EU MAA Procedure Advantages and Risks for Nonprescription Medicines.....	350
Table 32-1.	Overview of Good Pharmacovigilance Practices	381
Table 32-2.	Periodic Benefit-Risk Evaluation Report (PBRER), Development Safety Update Report (DSUR) and Risk Management Plan (RMP) Interchangeable Modules.....	385
Table 33-1.	ATMPs and Their Status in the EU, INN (International Nonproprietary Name)	396
Table 33-3.	ATMP Classification Definitions: GTMPs, CTMPs, TEPs and Combined ATMPs	399
Table 33-4.	Recent Examples ATMP Classification Outcomes by CAT	401
Table 33-5.	Guidance Documents Available for Cell Therapy Medicinal Products and Tissue-Engineered Products.....	404
Table 33-6.	Guidance Documents Available for Gene Therapy Medicinal Products	408
Table 33-7.	Definition of Starting Materials, Drug Substance and Drug Product	409
Table 34-1.	Serological Donor Testing Requirements	419
Table 34-2.	Structure of the Single European Code.....	420
Table 34-3.	General Applicable Regulatory Framework for Medical Products Containing Human Tissue Intended for Human Clinical Use and its Interconnection with Directive 2004/23/EC (<i>Tissues and Cells Directive</i>)	422
Table 34-4.	General and Specific Market Access Requirements for Tissue- and Cell-Based Products, Excluding ATMPs.....	423
Table 34-5.	Qualifications and Responsibilities of the Responsible Person Under the EUTCD, Qualified Person for Human Medicinal Products and Responsible Person for Regulatory Compliance Under the <i>EU MDR</i>	424
Table 38-1.	Medicinal Products Derived From Human Plasma and Their Indications.....	461
Table 42-1.	Food-Producing Species	510
Table 43-1.	A Complete List of All MEDDEV Guidances	522
Table 43-2.	EMA's Committees and Working Parties	527
Table 43-3.	National Competent Authorities	531
Table 43-4.	Eligible Industry Stakeholder Organisations	535
Table 43-5.	EDQM Databases.....	537